Scholar Rock Holding (SRRK)
NASDAQ:SRRK
Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$49.96
-$0.51(-1.26%)
At close: 4:00 PM EST
$49.96
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$27.07 - $52.19
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.26M
Market Cap
$5.35B
Enterprise Value$5.68B
Total Cash (Recent Filing)$479.94M
Total Debt (Recent Filing)$205.67M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 12, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding119,828,340
10 Day Avg. Volume1,240,108
30 Day Avg. Volume1,263,995
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.56K
Enterprise Value/Ebitda-14.25
Forecast
1Y Price Target
$60.36Price Target Upside20.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.19
Revenue Forecast (FY)$6.42M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: BLA Acceptance & PDUFAAcceptance of the BLA and a defined PDUFA date materially reduce timing uncertainty and create a clear regulatory path to commercialization. A favorable decision would transition Scholar Rock from a clinical-stage spender to a potential revenue generator and unlock milestone/financing triggers.
Dual Fill-finish Manufacturing StrategyFiling from two independent fill-finish sites and expectation of commercial supply from a second facility materially reduces single-site risk. This structural redundancy strengthens supply resilience for launch, mitigates prior CRL manufacturing exposure, and supports scalable commercial distribution.
Strong Cash Position And Financing OptionalityEnding Q1 with ~$480M plus debt/ATM access and an approval-linked $150M draw option gives the company multi-channel liquidity to fund pre-launch commercialization, ongoing trials and operating burn. This financing flexibility materially lowers near-term solvency risk ahead of potential approval.
Bears Say
No Product Revenue And Widening LossesThe company remains unprofitable with no product revenue and rapidly increasing net losses. Persistent, large negative earnings and cash consumption mean the business cannot self-fund operations long-term without successful approval, commercialization or sustained external financing.
Rising Debt And LeverageMaterial increase in debt and higher leverage reduces financial flexibility and raises refinancing, interest and covenant risks. Coupled with ongoing cash burn, rising indebtedness increases dependence on capital markets and the potential for dilutive financing if commercial milestones are delayed.
Manufacturing-related Approvability Uncertainty (Catalent Indiana)Regulatory classification of the Catalent Indiana facility remains unresolved and was the core issue in the prior CRL. Until classified favorably, approvability and European timing remain conditional, posing a sustained execution risk that could delay or constrain launch and revenue realization.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $27.07 and its highest was $52.19 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $5.35B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.03.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.84.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 119,828,340 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -1.401%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.36 (20.82% Upside)
$60.36 (20.82% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 183.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.27%
12-Months-Change
Fundamentals
Return on Equity
-163.52%
Trailing 12-Months
Asset Growth
31.33%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: FDA accepted the BLA with a clear PDUFA date (Sept 30, 2026), the company has created dual manufacturing paths (second facility supplying product in early Q3), European review appears on track for midyear, and the balance sheet and commercial infrastructure were strengthened during the quarter. Key risks remain focused on regulatory classification of the Catalent Indiana site, continued manufacturing/regulatory uncertainty until that classification, high pre-commercial operating spend, and the need to monetize financing levers (debt/ATM/PRV). On balance, the material positive developments (BLA acceptance, dual fill-finish strategy, clear supply path, strong cash position, pipeline progression and commercial readiness) outweigh the remaining lowlights and uncertainties.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$60.36
▲(20.82% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
20.61% Insiders
28.70% Mutual Funds
15.99% Other Institutional Investors
24.78% Public Companies and
Individual Investors